The fund focuses its investments on German equities from all segments, with the majority of investments being made in financially solid German large caps. Selected small and medium-size companies are also part of the investment mix. Particular emphasis is placed on an intensive contact with the company. Additionally, up to 10% of the fund's assets may be invested outside Germany. The fund is actively managed and the cash reserves can be dynamically managed depending on the market situation.
Responsible manager since inception
|Category:||Equity Funds German Blue Chips|
|VG/KVG:||Union Bancaire Privee, UBP SA|
|Fund Manager:||DJE Kapital AG|
|Type of Share:||accumulation|
|Financial Year:||01.01. - 31.12.|
|Fund Size (17/06/2021):||26,78 Mio EUR|
|TER p.a. (30/06/2020):||2,18 %|
|Reference Index:||100% DAX INDEX|
|Initial Charge:||3,00 %|
|Management Fee p.a.:||1,50 %|
|Custodian Fee p.a.:||0,10 %|
|Advisory Fee p.a.:||1,10 %|
Ratings & Awards (17/06/2021)
€uro Fund Award 2019
1st place over 20 years in the "Equity Funds Germany" category
Performance in Percent vs. Reference Index
|Standard Deviation (1 years):||11,49 %|
|Tracking Error (1 years):||22,32 %|
|Value at Risk (99% / 20 days):||-7,09 %|
|Maximum Drawdown (1 year):||-7,07 %|
|Sharpe Ratio (1 years):||1,68|
|Correlation (1 years):||0,00|
|Beta (1 years):||0,02|
|Treynor Ratio (1 years):||878,56|
Top Country Allocation (31/05/2021)
Asset Allocation (31/05/2021)
Germany is a country that has a lot to offer: It is not only by far the largest economy in the European Union (EU), but also the fourth largest in the world. Although Germany was home to only around 1.1 percent of the world's population in 2020, it accounted for 8.9 percent of global goods exports and 6.6 percent of goods imports in the same year, according to UNCTAD estimates. Germany is thus one of the world's most important export and import nations. Germany's growth is generated on a broadly diversified basis. In addition, Germany enjoys a leading global market position in key industries, including automotive, chemicals and mechanical engineering, thanks to its well-trained skilled workforce and the large number of small and medium-sized companies with high innovative strength. The high savings rate of consumers, the healthy real estate price development, the excellent infrastructure and the first-class quality of life also open up further potential. UBAM - Dr. Ehrhardt German Equity focuses on the further development and dynamics of German companies. The fund management invests not only in well-known large stocks from the German share index DAX, but also in medium-sized and smaller companies.
- Active management – high cash reserves can be built up ahead of sharp market falls
- Experienced fund manager following an investment approach based on fundamental, monetary and market-technical (FMM) analysis, which has a proven track record of over 45 years
- The mix of smaller and medium-size companies allows investors to profit from the small and mid-cap segment
- Issuer credit risks
- Equity prices may exhibit relatively strong fluctuations depending on market conditions
- Proven investment approach to date is no guarantee of future investment success
The German share index DAX performed well in May gaining a surplus in height of 1.88% because of better-than-expected earnings reported by companies for the first quarter of 2021 and of statements by the central banks of the euro area and the USA reassuring investors as the expansionary monetary policy will be continued with reference to financial stability. Finally the majority of economic indicators also increased including the purchasing managers' indices for industry and services as well as exports, which rose for the eleventh month in a row and the ifo business climate index. In this market environment the price of the UBAM Dr. Ehrhardt German Equity rose 1.49%. At the equity level the strongest contribution to the fund’s performance came from, among others, the Bonn-based logistics company Deutsche Post, the Baden-Württemberg-based building materials and construction chemicals company Sto and the Vienna-based construction company Strabag. Burdening for the fund’s performance on the other side was the Tübingen-based biopharmaceutical company Curevac, the Frankfurt-based Deutsche Börse and the Erlangen-based medical technology company Siemens Healthineers. During the month the fund management reduced the weighting of various sectors including automobiles, financial service providers, industry and household goods. Increased were basic materials, travel & leisure, telecommunications, healthcare and retail, among others. These adjustments reduced the fund's equity exposure to 94.26% at the end of the month, 96.90% previous month. As previous month bonds were not part of the portfolio at the end of the month.
Legal Information / Disclaimer:
Figures subject to revision by the auditors on the reporting dates. The published information does not constitute investment advice or a recommendation, but only provides a brief summary of the key features of the fund. The current sales documents (Key Investor Information Document, prospectus, annual report and – if the annual report is older than eight months – the semi-annual report) for the respective investment funds form the sole basis for the purchase of securities. The sales documents are available at no charge at the respective fund company, the distribution company or at www.dje.de. All data and estimates are indicative and may change at any time. This information is based on our assessment of current legal and tax regulations. The data were carefully compiled, but no guarantee can be given for the accuracy of such information. All data are subject to change. The performance is calculated using the BVI (Bundesverband Investment und Asset Management e.V.) method, i.e. without taking into account the subscription fee. Individual expenses such as fees, commissions and other charges are not taken into account in the data and would have a detrimental effect on the performance if they were. The subscription fees payable reduce the invested capital as well as the performance depicted. Data on past performance are not a reliable indicator of future performance. The tax treatment depends on the individual circumstances of the investor and may be subject to change. Please see the prospectus for more detailed tax information. In connection with brokering fund units, the Dr. Jens Ehrhardt Group and its distribution partners may receive reimbursements from costs charged to the funds by the investment companies in accordance with the respective prospectuses. The units of this fund that are issued may only be sold or offered for sale in jurisdictions in which such offer or sale is permitted. Therefore the units of this fund may not be offered for sale or sold in the USA, or offered for sale or sold to or for the account of US citizens or US persons resident in the USA. This document and the information it contains may not be distributed in the USA. The distribution and publication of this document and the offer or sale of units may also be subject to restrictions in other jurisdictions.
*) © 2016 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.